Litigation Details for DUKE UNIVERSITY v. AKORN, INC. (D.N.J. 2018)
✉ Email this page to a colleague
DUKE UNIVERSITY v. AKORN, INC. (D.N.J. 2018)
| Docket | ⤷ Sign Up | Date Filed | 2018-09-19 |
| Court | District Court, D. New Jersey | Date Terminated | 2019-10-15 |
| Cause | 35:271 Patent Infringement | Assigned To | Brian R. Martinotti |
| Jury Demand | Both | Referred To | Tonianne J. Bongiovanni |
| Patents | 7,351,404; 7,388,029; 8,038,988; 8,101,161; 8,263,054; 8,906,962; 8,926,953; 9,579,270 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in DUKE UNIVERSITY v. AKORN, INC.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for DUKE UNIVERSITY v. AKORN, INC. (D.N.J. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-09-19 | 1 | litigated other patents that cover LATISSE®, including U.S. Patent No. 7,388,029 (“the ’029 patent’), to which…infringement of U.S. Patent Nos. 9,579,270 (“the ’270 patent”) under the Patent Laws of the United States…exclusive license to the ’270 patent. 21. The ’270 patent has a patent term that expires on January…United States Patent and Trademark Office (“USPTO”) duly and legally issued the ’270 patent, entitled “…the ’270 patent is attached to this complaint as Exhibit A. 19. The ’270 patent is assigned | External link to document | |
| 2019-01-10 | 22 | Brief | following patents owned by Allergan that cover LATISSE®: Patent Nos. 7,351,404 (“’404 patent”); 8,038,988…988 patent”); 8,101,161 (“’161 patent”); 8,263,054 (“’054 patent”); and 8,926,953 (“’953 patent”). …litigated other patents that cover LATISSE®, including U.S. Patent No. 7,388,029 (“’029 patent”). The asserted…antitrust and patent misuse counterclaims is that Plaintiffs’ current and prior patent infringement …legal monopolies by the U.S. Patent and Trademark Office (“USPTO”). Once a patent issues, the First Amendment | External link to document |
| 2019-02-03 | 26 | Disposition of U.S. Patent No. 7,351,404 (“’404 patent”) …prosecute patent infringement lawsuits for the licensed patents, and agreed to join the patent lawsuits…ANDA infringed the ’404 patent and the ’029 patent. (Id. at ¶ 34.) Both patents are generally directed… ’404 patent and the asserted ’953 patent was a continuation of the invalidated ’029 patent. Allergan…the licensed patents, including the ’270 and ’962 patents, joint filing of multiple patent infringement | External link to document | |
| 2019-09-16 | 41 | Opinion | infringement of U.S. Patent Nos. 7,531,404 (the “’404 Patent”) and 7,388,029 (the “’029 Patent”) by Akorn’s …of: U.S. Patent No. 8,263,054 (the “’054 Patent”); U.S. Patent No. 8,038,988 (the “’988 Patent”); and …States Patent and Trademark Office (“USPTO”) issued U.S. Patent No. 9,579,270 (the “’270 Patent”), entitled…II court held that the ’988 Patent, the ’161 Patent, and the ’054 Patent are related to, and recite substantially…Product infringed U.S. Patent No. 8,906,962 (the “’962 Patent”) and U.S. Patent 4 Duke was not | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
